7 results
6-K
EX-99.1
MOR
Morphosys AG
30 Apr 24
First Quarter Interim Statement January – March 2024
8:57am
. In July 2023, HI-Bio announced that the first participants have been dosed in a Phase 1 healthy volunteer study of HIB210. I-Mab Biopharma holds
6-K
EX-99.1
MOR
Morphosys AG
20 Mar 24
Current report (foreign)
4:12pm
and South Korea. In July 2023, HI-Bio announced that the first participants have been dosed in a Phase 1 healthy volunteer study of HIB210. I-Mab
6-K
EX-99.1
MOR
Morphosys AG
13 Mar 24
Current report (foreign)
4:08pm
. In July 2023, HI-Bio announced that the first participants have been dosed in a Phase 1 healthy volunteer study of HIB210. I-Mab Biopharma holds
6-K
EX-99.1
MOR
Morphosys AG
16 Nov 23
Half-Year Report JANUARY – JUNE
9:25am
healthy volunteer study of HIB210. I-Mab Biopharma holds the exclusive rights for MOR210 in Greater China and South Korea and is currently investigating
6-K
EX-99.1
csf21
16 Nov 23
Third Quarter Interim Statement JANUARY – SEPTEMBER 2023
6:00am
6-K
EX-99.1
h71uby uf
10 Aug 23
Half-Year Report JANUARY – JUNE 2023
8:51am
- Prev
- 1
- Next